OmniScreen™ Cell Based Screening Service

Well-validated in vitro screening program for rapid and cost-effective screening of over 500 cell lines


Progress your Lead Compound to Validated Candidate with our Expanded OmniScreen

Use cost-effective, rapid, and large-scale cancer cell line screening to advance your lead compound to validated candidate. OmniScreen provides key information on the cytotoxicity and chemotherapeutic potential of your agent early in the drug development process.

Registration Deadline
Study Initiation
14th October 2020
26th October 2020
29th January 2021
16th February 2021
1st May 2021
10th May 2021
20th August 2021
1st September 2021

Well-Validated, Cost-Effective Screening

Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.

Highlights of OmniScreen:

  • High throughput screening of at least 50 cell lines per run to maximize your savings
  • Positive drug control and cell line revival costs are included as part of OmniScreen
  • Unique subpanels built from CrownBio’s proprietary menu of 500+ cancer cell lines
  • Enhanced cell line growth data for improved screening quality including:
    • Validated seeding densities across multiple time points
  • Choose the models that best fit your needs with XenoBase® our curated, online database of cancer cell lines
  • Select from quality cells STR verified and mycoplasma-proofed
  • Customize your study with flexible template designs
  • Quality control your data against standard of care agents
  • Obtain bioinformatics support throughout the study
  • Review your data in real time using a secure online client account

concept of a well validated, large-scale, in vitro, cancer cell line panel screening platform


OmniScreen, CrownBio’s Well Validated, Large-Scale Cell Panel Screening Platform

Focused Screening Panels

Our OmniScreen cancer cell line panels include:

  • OmniPanel™, a genomically diverse and growing collection of more than 500 cancer cell lines for drug response screening

  • XenoSelect™, a diverse oncogenic in vitro screening panel of more than 150 well validated cell lines with corresponding xenograft models ready for in vivo efficacy studies

  • RNAseq Panel, more than 170 in-house genomically characterized cell lines to correlate mutation status, copy number variation, and expression levels with drug response.

  • PrimePanel™, over 35 unique human disease-relevant cell lines derived from our patient-derived xenograft (PDX) models.

Contact us for more information